- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Patent holdings for IPC class A61P 19/10
Total number of patents in this class: 1874
10-year publication summary
|
50
|
31
|
77
|
120
|
105
|
98
|
96
|
103
|
94
|
69
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2707 |
33 |
| Novartis AG | 10685 |
22 |
| Daiichi Sankyo Company, Limited | 1879 |
22 |
| The Regents of the University of California | 20195 |
17 |
| Osaka University | 3396 |
17 |
| Radius Health, Inc. | 97 |
16 |
| Bristol-myers Squibb Company | 4847 |
12 |
| Merck Patent GmbH | 5770 |
12 |
| Boehringer Ingelheim International GmbH | 4632 |
11 |
| Amgen Inc. | 4141 |
11 |
| Chugai Seiyaku Kabushiki Kaisha | 1372 |
11 |
| Kyowa Hakko Kirin Co., Ltd. | 280 |
11 |
| Bayer Schering Pharma AG | 374 |
10 |
| Entera Bio Ltd. | 47 |
10 |
| Sanofi | 4113 |
10 |
| sanofi-aventis | 352 |
10 |
| Société des Produits Nestlé S.A. | 9342 |
9 |
| Wisconsin Alumni Research Foundation | 3890 |
9 |
| Asahi Kasei Pharma Corporation | 130 |
9 |
| Astellas Pharma Inc. | 1065 |
9 |
| Other owners | 1603 |